Research graph
References from Patient-Reported Benefits of Acoramidis Across Genotypes in Transthyretin Amyloid Cardiomyopathy: KCCQ and EQ-5D-5L Outcomes From ATTRibute-CM. Local targets link to admitted publications; unresolved targets remain external evidence.
Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis
10.1161/circulationaha.118.038169 · 2019 · External reference
Race, genetics, and social determinants of health in transthyretin cardiac amyloidosis: A literature review and call to action
10.1007/s11886-025-02220-z · 2025 · External reference
Efficacy of acoramidis in wild-type and variant transthyretin amyloid cardiomyopathy: results from ATTRibute-CM and its open-label extension
10.1001/jamacardio.2025.4477 · 2026 · External reference
Effect of acoramidis on heart failure-related health status: an analysis from the ATTRibute-CM study
10.1001/jamacardio.2026.2413 · 2026 · External reference
Unresolved reference
External reference
Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores
10.1016/j.jval.2016.11.015 · 2017 · External reference
Estimation of an instrument-defined minimally important difference in EQ-5D-5L index scores based on scoring algorithms derived using the EQ-VT version 2 valuation protocols
10.1016/j.jval.2020.03.003 · 2020 · External reference
A systematic literature review of important and meaningful differences in the EQ-5D index and visual analog scale scores
10.1016/j.jval.2024.11.006 · 2025 · External reference
